Stocks and Investing Stocks and Investing
Tue, June 25, 2024
Mon, June 24, 2024

Andrew Fein Reiterated (AMLX) at Strong Buy and Held Target at $8 on, Jun 24th, 2024


Published on 2024-10-28 12:04:17 - WOPRAI, Andrew Fein
  Print publication without navigation


Andrew Fein of HC Wainwright & Co., Reiterated "Amylyx Pharmaceuticals, Inc." (AMLX) at Strong Buy and Held Target at $8 on, Jun 24th, 2024.

Andrew has made no other calls on AMLX in the last 4 months.



There are 6 other peers that have a rating on AMLX. Out of the 6 peers that are also analyzing AMLX, 5 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Graig Suvannavejh of "Mizuho" Maintained at Hold with Decreased Target to $3 on, Tuesday, May 14th, 2024
  • Joel Beatty of "Baird" Maintained at Hold with Decreased Target to $3 on, Thursday, April 11th, 2024
  • Marc Goodman of "Leerink Partners" Downgraded from Buy to Hold on, Monday, March 11th, 2024
  • Chris Shibutani of "Goldman Sachs" Downgraded from Strong Buy to Hold and Decreased Target to $4 on, Monday, March 11th, 2024
  • Umer Raffat of "Evercore ISI Group" Downgraded from Buy to Hold on, Friday, March 8th, 2024


This is the rating of the analyst that currently disagrees with Andrew


  • Neena Bitritto-Garg of "Deutsche Bank" Maintained at Strong Buy with Decreased Target to $8 on, Monday, March 11th, 2024
Contributing Sources